Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry
investor experience and global policy expertise, replacing retiring
director Stephen Berenson
Co-founder and director Robert Langer also to retire from the Moderna
Board; recruitment efforts ongoing for his replacement
CAMBRIDGE, MA / ACCESSWIRE / July 23, 2024 / Moderna, Inc. (NASDAQ:MRNA)
today announced that David M. Rubenstein, Co-Founder and Co-Chairman of The
Carlyle Group, will join Moderna's Board of Directors, effective August 5,
2024. Upon Mr. Rubenstein's appointment, directors Robert Langer and Stephen
Berenson will also retire from the Board. Mr. Rubenstein will replace Mr.
Berenson on the Audit Committee of the Board. Both Dr. Langer and Mr.
Berenson have agreed to continue providing advisory services to the Company
on key matters following their Board retirement.
"As Moderna reaches its next stage of development as a commercial company
with global reach, we are honored to welcome David Rubenstein to the Board,"
said Noubar Afeyan, Co-Founder and Chairman of Moderna and Chief Executive
Officer of Flagship Pioneering. "David brings an incredibly rich depth of
experience investing in and growing businesses across a host of industries
as the Co-Founder, Co-Chairman, and former Co-CEO of The Carlyle Group. As
the Chairman of the Council on Foreign Relations and Chairman of the
Economic Club of Washington, D.C., David is also one of the most respected
voices globally on issues related to policy and international affairs, and
we welcome his insight as we execute on our global growth strategy."
"I am honored to join the Board of Directors at Moderna, a company at the
forefront of medical innovation and biotechnology," said David M.
Rubenstein. "Moderna's commitment to groundbreaking research and its role in
addressing global health challenges align deeply with my passion for
advancing scientific progress and improving lives. I look forward to
contributing to the continued success and transformative impact of this
remarkable organization."
"As we pursue our mission of delivering the greatest impact to people through mRNA medicines, David is the ideal partner to help guide our growth as we scale efficiently, while also reaching new markets and geographies," said Stéphane Bancel, Chief Executive Officer of Moderna. "We are privileged to have David join the Moderna Board, and we look forward to working together."
Dr. Afeyan continued, "I also want to thank Bob Langer and Stephen Berenson
for their many years of dedicated service to the Moderna Board. As one of
Moderna's co-founders, Bob is one of the visionaries responsible for making
mRNA medicines a reality, and his insights have enabled the company to
positively impact hundreds of millions of lives. Stephen joined the Board
before Moderna's initial public offering and has been instrumental in
guiding our growth over the last several years into a commercial company,
particularly through his service as Chair of the Compensation and Talent
Committee and a member of the Audit Committee. We will miss both of them and
wish them well."
"After many years of service as a co-founder and member of Moderna's Board
of Directors, I have decided that now is the right time for me to step
down," said Robert Langer, Sc.D. "It has been an honor to contribute to the
groundbreaking work and incredible progress the company has achieved."
"When I joined Moderna's Board of Directors seven years ago, I believed
Moderna had the potential to become one of the most impactful and valuable
pharmaceutical companies ever created," said Stephen Berenson. "Seven years
later, the company is well on its way to achieving those audacious goals,
and I'm immensely proud and honored to have been of service to the company
and its shareholders during that time."
Moderna's Nominating and Corporate Governance Committee anticipates
continuing to focus director recruitment efforts on individuals with
scientific and innovation experience following Dr. Langer's departure.
Mr. Rubenstein is Co-Founder and Co-Chairman of The Carlyle Group, and
previously served as the firm's Co-Chief Executive Officer. Mr. Rubenstein
is also the Chairman, Chief Executive Officer, and principal owner of the
Baltimore Orioles of Major League Baseball. Prior to forming Carlyle in
1987, Mr. Rubenstein practiced law in Washington, D.C. with Shaw, Pittman,
Potts & Trowbridge LLP (now Pillsbury Winthrop Shaw Pittman LLP). From
1977 to 1981, Mr. Rubenstein was Deputy Assistant to the President for
Domestic Policy. From 1975 to 1976, he served as Chief Counsel to the U.S.
Senate Judiciary Committee's Subcommittee on Constitutional Amendments. Mr.
Rubenstein is Chairman of the Boards of the Council on Foreign Relations,
the National Gallery of Art, the Economic Club of Washington, D.C., the John
F. Kennedy Center for the Performing Arts, and the University of Chicago and
serves on the Boards of Memorial Sloan-Kettering Cancer Center, Johns
Hopkins Medicine, the Institute for Advanced Study, the National
Constitution Center, the Brookings Institution, the Lincoln Center for the
Performing Arts, the American Academy of Arts and Sciences, and the World
Economic Forum.
Mr. Rubenstein is a magna cum laude graduate of Duke University,
where he was elected Phi Beta Kappa. Following Duke, Mr. Rubenstein
graduated from the University of Chicago Law School, where he was an editor
of the Law Review.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through
the advancement of mRNA technology, Moderna is reimagining how medicines are
made and transforming how we treat and prevent disease for everyone. By
working at the intersection of science, technology and health for more than
a decade, the company has developed medicines at unprecedented speed and
efficiency, including one of the earliest and most effective COVID-19
vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and
vaccines for infectious diseases, immuno-oncology, rare diseases and
autoimmune diseases. With a unique culture and a global team driven by the
Moderna values and mindsets to responsibly change the future of human
health, Moderna strives to deliver the greatest possible impact to people
through mRNA medicines. For more information about Moderna, please visit
modernatx.com and connect with us on X (formerly Twitter), Facebook,
Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended, including
statements regarding the composition of Moderna's Board of Directors, and
Moderna's future development. The forward-looking statements in this press
release are neither promises nor guarantees, and you should not place undue
reliance on these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are beyond
Moderna's control and which could cause actual results to differ materially
from those expressed or implied by these forward-looking statements. These
risks, uncertainties, and other factors include, among others, those risks
and uncertainties described under the heading "Risk Factors" in Moderna's
Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and
in subsequent filings made by Moderna with the U.S. Securities and Exchange
Commission, which are available on the SEC's website at www.sec.gov. Except
as required by law, Moderna disclaims any intention or responsibility for
updating or revising any forward-looking statements contained in this press
release in the event of new information, future developments or otherwise.
These forward-looking statements are based on Moderna's current expectations
and speak only as of the date of this press release.
###
Moderna Contacts
Media:
Chris Ridley
Head, Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.